Metformin was found to improve the survival and the effector function of CD8+ T cells under hypoxic conditions as well as reduce hypoxia‐induced apoptosis, while inhibiting PD1 and LAG3, thus improving the efficacy of cancer immunotherapy.20 Here, CD8A is linked to cancer.